Exenatide Once Weekly for Management of Type 2 Diabetes: A Review

References

• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742. doi:10.1038/nrendo.2012.140
   PubMed Web of Science ®Google Scholar
• Saisho Y. Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions. Ann Transl Med. 2018;6(7):131. doi:10.21037/atm.2018.02.24
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529. doi:10.1016/S0140-6736(18)32261-X
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. doi:10.1016/S0140-6736(19)31149-3
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896–907. doi:10.1056/NEJMoa2108269
   PubMed Web of Science ®Google Scholar
• Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–113. doi:10.1016/S2213-8587(17)30412-6
   PubMed Web of Science ®Google Scholar
• Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–662. doi:10.1016/S2213-8587(21)00203-5
   PubMed Web of Science ®Google Scholar
• Association AD. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl1):S111–s24.
   PubMed Web of Science ®Google Scholar
• Knop FK, Brønden A, Vilsbøll T. Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opin Pharmacother. 2017;18(6):555–571. doi:10.1080/14656566.2017.1282463
   PubMed Web of Science ®Google Scholar
• Heimbürger SM, Brønden A, Johansen NJ, et al. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. Expert Opin Pharmacother. 2019;20(5):501–510. doi:10.1080/14656566.2019.1571040
   PubMed Web of Science ®Google Scholar
• Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from Guinea pig pancreas. J Biol Chem. 1992;267(11):7402–7405. doi:10.1016/S0021-9258(18)42531-8
   PubMed Web of Science ®Google Scholar
• DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145–1154. doi:10.1089/dia.2011.0050
   PubMed Web of Science ®Google Scholar
• Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487–1493. doi:10.2337/dc06-2375
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250. doi:10.1016/S0140-6736(08)61206-4
   PubMed Web of Science ®Google Scholar
• Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33(6):1255–1261. doi:10.2337/dc09-1914
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–439. doi:10.1016/S0140-6736(10)60590-9
   PubMed Web of Science ®Google Scholar
• Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011;28(6):705–714. doi:10.1111/j.1464-5491.2011.03301.x
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234–2243. doi:10.1016/S0140-6736(10)60406-0
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252–258. doi:10.2337/dc11-1107
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–1310. doi:10.1210/jc.2010-2081
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117–124. doi:10.1016/S0140-6736(12)61267-7
   PubMed Web of Science ®Google Scholar
• Guja C, Frías JP, Somogyi A, et al. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study. Diabetes Obes Metab. 2018;20(7):1602–1614. doi:10.1111/dom.13266
   PubMed Web of Science ®Google Scholar
• Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004–1016. doi:10.1016/S2213-8587(16)30267-4
   PubMed Web of Science ®Google Scholar
• Genovese S, Mannucci E, Ceriello A. A review of the long-term efficacy, tolerability, and safety of exenatide once weekly for type 2 diabetes. Adv Ther. 2017;34(8):1791–1814. doi:10.1007/s12325-017-0499-6
   PubMed Web of Science ®Google Scholar
• Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18(3):203–216. doi:10.1111/dom.12591
   PubMed Web of Science ®Google Scholar
• MacConell L, Gurney K, Malloy J, et al. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4328 patients. Diabetes Metab Syndr Obes. 2015;8:241–253. doi:10.2147/DMSO.S77290
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Saisho Y, Inaishi J, et al. Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes. J Diabetes Investig. 2020;11(2):382–388. doi:10.1111/jdi.13146
   PubMed Web of Science ®Google Scholar
• Ji L, Onishi Y, Ahn CW, et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4(1):53–61. doi:10.1111/j.2040-1124.2012.00238.x
   PubMed Web of Science ®Google Scholar
• Onishi Y, Koshiyama H, Imaoka T, et al. Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4(2):182–189. doi:10.1111/jdi.12000
   PubMed Web of Science ®Google Scholar
• Inaishi J, Saisho Y, Watanabe Y, et al. Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study. BMC Endocr Disord. 2022;22(1):20. doi:10.1186/s12902-022-00932-9
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239. doi:10.1056/NEJMoa1612917
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. doi:10.1056/NEJMoa1509225
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851. doi:10.1056/NEJMoa1901118
   PubMed Web of Science ®Google Scholar
• Nagahisa T, Saisho Y. Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Ther. 2019;10(5):1733–1752. doi:10.1007/s13300-019-00680-5
   PubMed Web of Science ®Google Scholar
• Sharma D, Verma S, Vaidya S, et al. Recent updates on GLP-1 agonists: current advancements & challenges. Biomed Pharmacother. 2018;108:952–962. doi:10.1016/j.biopha.2018.08.088
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Sorli CH, Trautmann ME, et al. Once-weekly efpeglenatide dose-range effects on glycemic control and body weight in patients with type 2 diabetes on metformin or drug naive, referenced to liraglutide. Diabetes Care. 2019;42(9):1733–1741. doi:10.2337/dc18-2648
   PubMed Web of Science ®Google Scholar
• Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258–266. doi:10.2337/dc17-0417
   PubMed Web of Science ®Google Scholar
• Unni S, Wittbrodt E, Ma J, et al. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):468–473. doi:10.1111/dom.13107
   PubMed Web of Science ®Google Scholar
• Giugliano D, Chiodini P, Maiorino MI, et al. Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis. J Endocrinol Invest. 2019;42(10):1165–1169. doi:10.1007/s40618-019-01047-0
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131–138. doi:10.1016/S0140-6736(19)31150-X
   PubMed Web of Science ®Google Scholar
• Bethel MA, Mentz RJ, Merrill P, et al. Renal outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes. 2018;67(Suppl1):522–P. doi:10.2337/db18-522-P
   Web of Science ®Google Scholar
• van der Aart-van der Beek AB, Clegg LE, Penland RC, et al. Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: a post hoc analysis of the EXSCEL trial. Diabetes Obes Metab. 2020;22(12):2493–2498. doi:10.1111/dom.14175
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• Saisho Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 2020;8(2):14. doi:10.3390/diseases8020014
   PubMed Web of Science ®Google Scholar
• Koska J, Migrino RQ, Chan KC, et al. The effect of exenatide once weekly on carotid atherosclerosis in individuals with type 2 diabetes: an 18-month randomized placebo-controlled study. Diabetes Care. 2021;44(6):1385–1392. doi:10.2337/dc20-2014
   PubMed Web of Science ®Google Scholar
• Nauck MA, Quast DR. Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6. Front Endocrinol (Lausanne). 2021;12:645566. doi:10.3389/fendo.2021.645566
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Cox EJ, Neumiller JJ, et al. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat Rev Nephrol. 2021;17(4):227–244. doi:10.1038/s41581-020-00367-2
   PubMed Web of Science ®Google Scholar
• Wysham CH, MacConell LA, Maggs DG, et al. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. Mayo Clin Proc. 2015;90(3):356–365. doi:10.1016/j.mayocp.2015.01.008
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Wysham CH, Hardy E, et al. Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: an open-label extension of the DURATION-1 study. J Diabetes Complications. 2019;33(3):223–230. doi:10.1016/j.jdiacomp.2018.11.012
   PubMed Web of Science ®Google Scholar
• Qin L, Chen S, Flood E, et al. Glucagon-like Peptide-1 receptor agonist treatment attributes important to injection-naïve patients with type 2 diabetes mellitus: a Multinational Preference Study. Diabetes Ther. 2017;8(2):321–334. doi:10.1007/s13300-017-0230-2
   PubMed Web of Science ®Google Scholar
• Qiao Q, Ouwens MJ, Grandy S, et al. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diabetes Metab Syndr Obes. 2016;9:201–205. doi:10.2147/DMSO.S99732
   PubMed Web of Science ®Google Scholar
• Hauber AB, Nguyen H, Posner J, et al. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Curr Med Res Opin. 2016;32(2):251–262. doi:10.1185/03007995.2015.1117433
   PubMed Web of Science ®Google Scholar
• Healio. FDA approves once-weekly exenatide for children with type 2 diabetes. Available from: https://www.healio.com/news/Endocrinology/20210723/fda-approves-onceweekly-exenatide-for-children-with-type-2-diabetes. Accessed September 2, 2021.
   Google Scholar
• Weghuber D, Forslund A, Ahlström H, et al. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity. Pediatr Obes. 2020;15(7):e12624. doi:10.1111/ijpo.12624
   PubMed Web of Science ®Google Scholar
• Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664–1675. doi:10.1016/S0140-6736(17)31585-4
   PubMed Web of Science ®Google Scholar
• Mulvaney CA, Duarte GS, Handley J, et al. GLP-1 receptor agonists for Parkinson’s disease. Cochrane Database Syst Rev. 2020;7(7):Cd012990. doi:10.1002/14651858.CD012990.pub2
   PubMed Web of Science ®Google Scholar
• Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest. 2013;123(6):2730–2736. doi:10.1172/JCI68295
   PubMed Web of Science ®Google Scholar
• Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):859–869. doi:10.1016/S2213-8587(18)30268-7
   PubMed Web of Science ®Google Scholar